Medistim ASA (LTS:0OCD) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0OCD Medistim ASA LTS:0OCD
100 GF Score
Price kr231.00
GF Value kr260.85
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Medistim ASA Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Medistim ASA is: Low Risk: Strong fundamentals, worth long-term holding.

Medistim ASA  (LTS:0OCD) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Medistim ASA Risk Assessment Related Terms

LTS:0OCD vs ABT, SYK, MDT: Risk Assessment Comparison

For the Medical Devices subindustry, Medistim ASA's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medistim ASA Risk Assessment vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medistim ASA's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Medistim ASA's Risk Assessment falls into.


LTS:0OCD
100GF Score
Medistim ASA LTS:0OCD
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Medistim ASA (LTS:0OCD) Overvalued in 2026?

Based on GuruFocus' analysis, Medistim ASA stock appears to be undervalued. The current stock price of kr231.00 is trading 11.4% below its estimated GF Value™ of kr260.85. GuruFocus considers Medistim ASA to be Modestly Undervalued.

Key valuation signals for LTS:0OCD:

  • Risk Assessment:
  • GF Value™: kr260.85 vs. price of kr231.00 (11.4% below fair value)
  • GF Score™: 100/100 with 1 warning sign

No single metric tells the full story. See the LTS:0OCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medistim ASA Business Description

Address Okernveien 94, Oslo, NOR, 0579
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
100GF Score

Get the complete analysis for LTS:0OCD

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr231.00
Price
kr260.85
GF Value